Perspective Therapeutics (CATX) Other Working Capital Changes (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Other Working Capital Changes came in at $155000.0 in Q2 2026, down 52.6% quarter-over-quarter from $327000.0 in Q1 2026.
Analysis
Perspective Therapeutics (CATX) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Other Working Capital Changes across 17 years of filings, most recently posting $155000.0 for Q2 2026.
- In Q2 2026, Other Working Capital Changes changed N/A year-over-year to $155000.0; the TTM figure through Jun 2026 stood at $482000.0 (up 134.43% YoY), while the FY2025 annual figure was -$1.4 million, down 105.0% from the prior year.
- Other Working Capital Changes came in at $155000.0 for Q2 2026 at Perspective Therapeutics, down from $327000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $28.0 million in Q1 2024 to a low of -$1.4 million in Q1 2025.
- Average Other Working Capital Changes over 5 years is $2.3 million, with a median of $191000.0 recorded in 2022.
- Year-over-year, Other Working Capital Changes tumbled 9900.0% in 2022 and soared 46566.67% in 2024.
- Over 5 years, Other Working Capital Changes stood at $249000.0 in 2022, then surged by 35.34% to $337000.0 in 2023, then soared by 8208.61% to $28.0 million in 2024, then slumped by 105.0% to -$1.4 million in 2025, then jumped by 111.07% to $155000.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were $155000.0 in Q2 2026, $327000.0 in Q1 2026, and -$1.4 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 155,000.00 |
| Jun 30, 2026 | 155,000.00 |
| Mar 31, 2026 | 327,000.00 |
| Mar 31, 2026 | 327,000.00 |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Dec 31, 2023 | 337,000.00 |
| Dec 31, 2023 | 337,000.00 |
| Sep 30, 2023 | -457,000.00 |
| Sep 30, 2023 | -457,000.00 |
| Jun 30, 2023 | 385,000.00 |
| Jun 30, 2023 | 385,000.00 |
| Mar 31, 2023 | 60,000.00 |
| Mar 31, 2023 | 60,000.00 |
| Dec 31, 2022 | 249,000.00 |
| Dec 31, 2022 | 249,000.00 |
| Sep 30, 2022 | 227,000.00 |
| Sep 30, 2022 | 227,000.00 |